Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan

Hidradenitis suppurativa (HS) is a painful chronic skin disease characterized by abscesses, nodules, and tunnels in the skin. Adalimumab, a monoclonal antibody against tumor necrosis factor‐α, is approved for the treatment of HS in Europe, the USA, and Japan. This multicenter, open‐label, post‐marke...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Nobukazu, Hayama, Koremasa, Takahashi, Kenzo, Kurokawa, Ichiro, Okazaki, Masateru, Kashiwagi, Tomoko, Iwashita, Eri, Terui, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305509/
https://www.ncbi.nlm.nih.gov/pubmed/35040156
http://dx.doi.org/10.1111/1346-8138.16297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305509/
https://www.ncbi.nlm.nih.gov/pubmed/35040156
http://dx.doi.org/10.1111/1346-8138.16297

Ejemplares similares